Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H29N3O5 |
| Molecular Weight | 367.44 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)[C@@H](O)CNC(C)(C)C
InChI
InChIKey=ANZXOIAKUNOVQU-HNNXBMFYSA-N
InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3/t15-/m0/s1
| Molecular Formula | C18H29N3O5 |
| Molecular Weight | 367.44 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
(R)-Bambuterol is a selective β2-adrenoceptor agonist. R-Bambuterol Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currenTLy on the market. Laevo-Bambuterol was approved by the China Food and Drug Administration for the treatment of asthma.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
149.2 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26137575/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-BAMBUTEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1136 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26137575/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-BAMBUTEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
419.4 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26137575/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-BAMBUTEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Highly enantioselective synthesis, crystal structure, and circular dichroism spectroscopy of (R)-bambuterol hydrochloride. | 2008 Jul |
|
| A sensitive LC-MS/MS method for simultaneous determination of R-bambuterol and its active metabolite R-terbutaline in human plasma and urine with application to a clinical pharmacokinetic study. | 2014 Jul |
|
| The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study. | 2015 Apr |
|
| Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs. | 2015 Dec |
|
| Resolution of Rac-Bambuterol via Diastereoisomeric Salt Formation with o-Chloromandelic Acid and Differences in the Enantiomers' Pharmacodynamical Effects in Guinea Pigs and Beagles. | 2016 Apr |
|
| In vivo metabolism study of (R)-bambuterol in humans using ultra high performance liquid chromatography with tandem mass spectrometry. | 2016 Aug |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:43:42 UTC 2023
by
admin
on
Sat Dec 16 08:43:42 UTC 2023
|
| Record UNII |
U44CBZ5I3E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6604443
Created by
admin on Sat Dec 16 08:43:42 UTC 2023 , Edited by admin on Sat Dec 16 08:43:42 UTC 2023
|
PRIMARY | |||
|
788821-30-7
Created by
admin on Sat Dec 16 08:43:42 UTC 2023 , Edited by admin on Sat Dec 16 08:43:42 UTC 2023
|
PRIMARY | |||
|
U44CBZ5I3E
Created by
admin on Sat Dec 16 08:43:42 UTC 2023 , Edited by admin on Sat Dec 16 08:43:42 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER | |||
|
|
SALT/SOLVATE -> PARENT |
